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Meeting Report
Second U.K. Workshop on the enhancement of
chemotherapy by nitroimidazoles
Held at MRC Clinical Oncology Unit, Cambridge, October 7th, 1982
(Rapporteurs, P.R. Twentyman & P. Workman)
There is considerable current interest amongst
scientists and clinicians in the combined use of
nitroimidazoles such as misonidazole (MISO) and
cytotoxic chemotherapy. This meeting was arranged
to review progress in the field since the first U.K.
Workshop held at the CRC. Gray Laboratory and
the International meeting at Key Biscayne, Florida
in June and September, 1981 respectively (Fowler,
1982; Sutherland, 1982). It was attended by 30
invited participants from the U.K., nearly all of
whom are active workers in the field, and data
contributions were also made by Drs. J.M. Brown
and D. Hirst (Stanford) and Dr. D. Siemann
(Rochester, New York).
Each of 4 sessions was introduced by a reviewer,
who summarised the published literature. This was
followed by short proferred presentations of recent
data. The titles of the sessions were (i) In vitro; (ii)
In vivo - single high dose; (iii) In vivo - multiple
dosing and (iv) clinical. The meeting was
introduced by Prof. N.M. Bleehen. The first 2
sessions were chaired by Prof. J.F. Fowler and the
final 2 by Dr. G.G. Steel.
In this account, we report the main points
emerging from the discussions without attribution
to individual contributors. We have done this in
order to keep the account as concise as possible.
(i) In vitro (reviewed by I. Stratford; proferred
presentations by P. Twentyman, B. Millar). Pre-
incubation of cells under hypoxic conditions with
5mM MISO sensitizes them to subsequent
treatment under aerobic conditions with 8 cytotoxic
drugs (mostly alkylating agents and nitrosoureas)
but protects against adriamycin and mAMSA.
Evidence continues to accumulate that such
hypoxic pre-incubation of cells with nitroimidazoles
leads to (a) depletion of non-protein thiols and (b)
interference with fixation and/or repair of DNA
damage by cytotoxic drugs. Both of these
phenomena appear to be involved in sensitization
but their relative contributions and the precise
mechanism remains to be resolved. Increasing the
electron affinity of the sensitizer generally produces
greater chemosensitization. Changes in lipophilicity
are considerably less important. At clinically
achievable sensitizer concentrations (e.g. 100,ug
ml-' for MISO), maintained for prolonged periods
(e.g. 16h) sensitization to melphalan but not to
CCNU was seen in EMT6 tumour spheroids.
Experiments do not appear to have been carried
out in which the cytotoxic drug exposure following
pre-incubation has also been performed under
hypoxic conditions. It was felt that, despite the
technical problems, such experiments are necessary.
(ii) In vivo - single high dose in the mouse
(reviewed by T. Stephens; proferred presentations
by J. Millar, P. Sheldon, P. Workman, F. Lee).
Twenty-five published papers were reviewed which
reflects the attention that this aspect has received.
A problem arises in that enhancement ratios cannot
be estimated from many of the reports. In by far
the majority of the reports there were indications
that enhancement of tumour response in mice was
greater than that of normal tissue toxicity (usually
assessed in terms of acute LD50 and depression of
bone marrow CFUs or peripheral leucocyte count).
The range of cytotoxic drugs which is enhanced by
high dose MISO is generally similar to that seen in
vitro with the notable exception of cis-platinum, for
which in vitro but not in vivo enhancement occurs.
In most, but not all, studies chemosensitization is
largely lost at MISO doses below 0.3-0.5g kg-1.
Several groups have investigated alternative
sensitizers to MISO, particularly lipophilic
analogues (e.g. benznidazole, Ro 03-8799, Ro 07-
1902) and analogues containing an alkylating
function (e.g. RSU 1069), mostly in combination
with CCNU or melphalan. With both these types of
sensitizer it is possible to produce either greater
sensitization than for equivalent doses of MISO or
equal sensitization to that achievable with MISO
but at lower doses. On balance, data for the
combination of low doses of benznidazole with
CCNU suggest that the therapeutic gain is similar
to that seen for high dose MISO with CCNU.
In some cases, but not all, the drug metabolism
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inhibitor SKF 525A can give similar
chemosensitization to MISO. It is now clear that in
mice major alterations in cytotoxic drug
pharmacokinetics are caused by single high dose
sensitizer pretreatment. Increases in both plasma
and tumour concentrations of cytotoxic drugs
(CCNU, chlorambucil, melphalan and
cyclophosphamide) have been demonstrated.
Relative changes in different pharmacokinetic
parameters could conceivably lead to changes in
therapeutic ratio.
(iii) In vivo - multiple doses in the mouse
(reviewed by N. McNally; proferred presentations
by P. Twentyman, M. Hinchcliffe, J. Denekamp
and V. Randhawa, F. Lee). In order to simulate
human pharmacokinetics several groups have now
investigated the possibility of chemosensitization by
maintaining clinically-achievable plasma
concentrations of MISO in mice. The multiple dose
regimes were all similar to those used originally by
the Stanford group. For MISO exposures of 100jug
ml-' for 6-8h, the data are conflicting, even where
different groups have used the same drug
combinations in nominally identical tumour
systems. It was suggested that such exposures may
be close to some threshold for the onset of
chemosensitization. One report indicated that
extending the MISO exposure period from 7 to 16h
may produce increased sensitization to
cyclophosphamide. Large changes in cytotoxic drug
pharmacokinetics do not appear to be caused by
these multiple MISO regimes.
(iv) Clinical (reviewed by T. McElwain; proferred
presentation by T. Roberts). Several small Phase I
clinical trials have been or are being carried out
combining MISO with cytotoxic drugs. In addition
the combination of CCNU and benznidazole is
being investigated. In general it does not appear
that major increases in cytotoxic drug toxicities are
brought about by the addition of 2-3g m 2 of
MISO to one or more treatments. In one study it
was found that the pharmacokinetics of high dose
melphalan were not changed by the addition of
MISO.
At the end of the meeting a lengthy and
enthusiastic period of discussion was initiated with
a summary by Prof. G.E. Adams. It is still difficult
to relate in vivo sensitization to the in vitro hypoxic
pre-incubation effect. In vitro experiments at much
lower sensitizer concentrations are needed, as are
experiments in which the full procedure, from pre-
incubation to assay, is carried out under hypoxic
conditions. There is a disparity between the
dependence of in vitro and in vivo
chemosensitization upon sensitizer lipophilicity and
electron affinity. There was some disagreement as
to the implications of this finding for the
mechanism of the two effects. As far as in vivo
sensitization is concerned, the relative contributions
of changes in cytotoxic drug pharmacokinetics and
of hypoxia-mediated events remains unsettled.
There is now no doubt that pharmacokinetic
changes in the mouse are brought about by single
high dose sensitizer pretreatment. For multiple low
dose regimes, however, they appear to be less
important. Experiments on chemosensitization in
tumours of different sizes were not considered to
provide definitive evidence for a hypoxia-dependent
mechanism. A more stringent test would be
provided by experiments in which the extent of
tumour hypoxia is manipulated artificially. At the
cellular level further studies are needed regarding
the effects of chemosensitizers on drug uptake and
on DNA damage.
If data from Phase I clinical trials continue to
reveal no undue increase in normal tissue toxicity
for sensitizer/cytotoxic drug combinations, then
Phase II studies are likely to proceed. The most
suitable tumours for such studies are the initially-
sensitive tumours in relapse (e.g. non-Hodgkins'
lymphomas) or the advanced tumours for which
chemotherapy is given palliatively and where length
of remission provides a quantitative measure of
response.
Thanks were expressed for the financial assistance
provided towards the meeting costs by Roche (Welwyn)
Ltd. and by the University of Cambridge, Department of
Clinical Oncology and Radiotherapeutics.
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